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Abstract 
A rising incidence of oropharyngeal squamous cell carcinoma (OPSCC) incidence has occurred 
throughout the developed world, where it has been attributed to an increasing impact of human 
papillomavirus (HPV) on disease etiology. This report presents the findings of a multicenter cross-
sectional retrospective study aimed at determining the proportion of HPV-positive and HPV-negative 
OPSCC within the United Kingdom (UK). Archival tumor tissue blocks from 1602 patients previously 
diagnosed with OPSCC (2002-2011) were collated from 11 centers. HPV status was determined with 
3 validated commercial tests to provide valid data for 1474 cases in total. Corresponding national 
incidence data from the same decade were obtained from UK Cancer registries. The overall 
proportion of HPV+ OPSCC between 2002-2011 was 51.8% (95% CI:49.3, 54.4) and this remained 
unchanged throughout the decade (unadjusted risk ratio:1.00 (95% CI:0.99, 1.02). However, over the 
same period, the incidence of OPSCC in the broader UK population underwent a 2-fold increase (age 
standardised rate (ASR) 2002:2.1 (95% CI:1.9, 2.2); 2011:4.1(95% CI:4.0, 4.3)). Although the number 
of OPSCC diagnosed within the UK from 2002-2011 nearly doubled, the proportion of HPV+ cases 
remained static at ~50%. Our results argue that the rapidly increasing incidence of OPSCC in the UK 
cannot be solely attributable to the influence of HPV. The parallel increase in HPV+ and HPV- cases 
we documented warrants further investigation, so that appropriate future prevention strategies for 
both types of disease can be implemented. 
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Introduction 
The developed world has experienced a dramatic rise in oropharyngeal squamous cell carcinoma 
(OPSCC) incidence.[1, 2] In England, the Age-Standardised incidence Rate (ASR) for OPSCC 
approximately tripled in men (from 2.0 to 5.8) and doubled in women (from 0.8 to 1.7) between 
1995 and 2011.[3] Associations between tobacco and alcohol consumption and OPSCC are well 
established,[4] however sexual behaviour is also a risk factor, with lifetime number of oral sex 
partners recognised as the behavioural measure most strongly associated with OPSCC 
development.[5] Changes in sexual behaviour appear to underlie the increasing proportion of OPSCC 
attributable to oncogenic Human papillomavirus (HPV).[1, 4, 6] Several North American and 
European studies have confirmed sharp rises in HPV-induced OPSCC incidence, although the exact 
proportion of HPV-positive tumours within the total disease burden varies considerably by 
geographical region.[7-11] 
In the UK, the proportion of OPSCC attributable to HPV has been assessed in several single-centre 
studies, however each was small, applied diverse methodology and had restricted geographical 
coverage.[12-14] The current pan-UK study aimed to assess the proportion of OPSCC attributable to 
HPV infection in a large contemporary sample (2002-2011 inclusive) using robust, standardised 
methods. There is a pressing need for these data to facilitate health economic analyses and to 
inform evidence-based policy-making with regard to prophylactic male HPV vaccination, as has 
recently been implemented in Australia.[15, 16]    
 
Methods   
Case selection 
The study received Research Ethics Committee approval (REC 11/NQ/0452). Northern Ireland 
samples were accessed under approvals from the Northern Ireland Biobank (NIB 11/001). OPSCC 
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was defined as cancers involving the base of tongue (C01), soft palate and uvula (C05.1 & C05.2), 
tonsil (C09) and oropharynx-not-otherwise-specified (C10.9). OPSCC cases diagnosed between 2002 
and 2011 (inclusive) were collected from 11 recruiting centres distributed across the UK to ensure 
results were not distorted by effects in one area or centre (Belfast, Bristol, Cardiff, Coventry, 
Edinburgh, Liverpool, London, Manchester, Newcastle, Poole and Southampton). The overall target 
sample-size (1710) was sufficient to allow comparison of prevalence between years with 7.5% 
precision. The number of samples per centre was determined pragmatically, based on the number of 
cases seen annually at each centre.  To avoid selection bias, the first 17 cases per year (11 cases for 
Coventry and Bristol) with available formalin-fixed paraffin embedded (FFPE) tumour blocks were 
included (irrespective of the definitive treatment modality employed). A representative FFPE block, 
either from diagnostic or resection specimen, was selected. Gender, age at diagnosis, year of 
diagnosis and histological diagnosis, including anatomical subsite classification, were recorded.  
 
HPV testing 
Sections of each FFPE block were taken for DNA analysis. To prevent DNA contamination, the 
microtome was thoroughly cleaned between specimens and a new blade used for each block. Tissue 
microarrays (TMA) were constructed for p16 immunohistochemistry (IHC) and high risk HPV DNA in-
situ hybridisation (ISH) testing as previously described.[17] Following construction, haematoxylin and 
eosin-stained sections of the TMAs were analysed to confirm accuracy of sampling. Samples were 
considered adequate only if all three TMA cores included tumour. 
For PCR, DNA was extracted from 2x10 µm FFPE whole sections by digestion for 16 hours in 
Tris50mM/EDTA1mM/Tween0.5% with 1mg/mL Proteinase K at 56°C, followed by heat inactivation 
(100°C for 5 mins) and centrifugation. Extracted DNA was tested for HPV DNA presence using the 
Optiplex HPV Genotyping Kit (Diamex GmbH, Heidelberg, Germany) according to the manufacturer’s 
instruction. This assay uses luminex technology to detect 24 common HPV types 
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(6,11,16,18,26,31,33,35,39,42,43,44,45,51,52,53,56,58,59,66,68,70,73 and 82). PCRs were 
performed using the Qiagen Multiplex PCR Kit (Qiagen GmbH, Hilden, Germany). The assay includes 
primers for amplification of the human ß-globin gene to confirm sample adequacy. Appropriate 
controls were included for sectioning (blank paraffin block), DNA extraction (reagent blanks), and 
HPV testing (HPV-positive Caski cell line DNA positive control and water negative control). 
p16 IHC was undertaken as a surrogate marker of HPV oncogene expression[18] using a proprietary 
kit (CINtec p16 Histology, Ventana Medical Systems, Mountain View, USA) on a Ventana Benchmark 
Autostainer. p16 IHC was scored as positive if there was strong and diffuse nuclear and cytoplasmic 
staining present in greater than 70% of malignant cells.[18] All other patterns were scored as 
negative.  
High-risk HPV DNA ISH was carried out using proprietary reagents (Inform HPV III Family 16 Probe(B), 
Ventana Medical Systems, Mountain View, USA) on a Ventana Benchmark Autostainer. This test 
detects high-risk HPV genotypes 16,18,31,33,35,39,45,51,52,56,58 and 66 and tumours were scored 
as positive if any blue reaction product co-localised with the nuclei of malignant cells.[19] Focal 
specific staining of only part of the tumour section was regarded as positive. Diffuse staining of 
tumour and stromal tissues, representative of non-specific chromogen precipitate, was scored as 
negative. Pale staining limited to the nucleoli of cells and staining of occasional leucocytes and 
stromal cells was also disregarded, in line with the manufacturer’s instructions. 
All p16 IHC and high-risk HPV DNA ISH testing was undertaken in UK hospital pathology laboratories 
holding Clinical Pathology Accreditation (CPA (UK) Ltd). Both tests are registered in vitro diagnostic 
devices for clinical use and as such carry CE marking, with associated methodological validation. Test 
results were scored by a panel of experienced head and neck pathologists, all of whom are 
accredited UK pathologists and members of the National Head and Neck Histopathology External 
Quality Assurance scheme administered by the Royal College of Pathologists. For quality assurance, 
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the panel undertook a calibration exercise on a training set of OPSCC cases (whole sections and 
TMAs) prior to scoring the study material. 
 
HPV status classification  
All cases were tested using the three HPV-detection assays, and were classified as HPV-positive if 
they showed evidence of both HPV gene expression (indicated by p16 IHC) and HPV DNA (indicated 
by ISH and/or PCR). A diagnostic algorithm utilising p16 IHC, HR HPV DNA ISH and PCR in a stepwise 
fashion was applied.[19, 20] The results of individual HPV diagnostic tests, and clinically relevant 
combinations of tests are also reported.  
 
Incidence Data 
Contemporaneous data on cancer incidence were obtained from Office of National Statistics (ONS) 
in England, NHS National Services Scotland, Northern Ireland Cancer Registry and Welsh Cancer 
Intelligence & Surveillance Unit.  Age standardised rates (ASR) were calculated, for the following 
groups: oropharyngeal cancers (comprised of C01, base of tongue; C05.1, soft palate; C05.2, uvula; 
C09, tonsil; C10.9, oropharynx not-otherwise-specified); laryngeal (C32); and mouth cancers (IARC 
definition, comprising C03, gum; C04, floor of mouth; C05, palate [excluding C05.1, soft palate and 
C05.2, uvula]; and C06, other and unspecified parts of mouth), as representative head and neck 
subsites not associated with HPV infection.[20] ASR were calculated using the updated 2013 
European Standard Population, and mid-2012 UK population estimates.[21]  
 
Statistical analysis 
9 
 
The characteristics of included cases (gender, age at diagnosis, oropharyngeal subsite, year of 
diagnosis and study centre) were described using frequencies/percentages or means/standard 
deviations as appropriate. Characteristics were compared with excluded cases, and with Cancer 
Registry data using t-tests or chi-squared tests as appropriate. The proportion of HPV-associated 
cases was calculated for the whole sample, then for each subset (with 95% confidence intervals). 
Age was the only continuous variable, and was categorised into five groups. The proportion of cases 
positive by p16 IHC, high-risk HPV DNA ISH and HPV PCR was also calculated to allow comparison 
with studies reporting these endpoints, as was the prevalence of HPV types among cancers caused 
by a single HPV type. Trends in the proportion of HPV-associated cancers over time were assessed 
using Poisson regression with robust error variance.[22] This approach was used because odds ratios 
(obtained from logistic regression) are poor approximations of risk ratios if the outcome prevalence 
is high.  Models were fitted before and after adjusting for sample characteristics. Finally, HPV-
positive proportions determined in the current study were applied to the UK incidence data to 
estimate the burden of oropharyngeal cancers caused by HPV over the period. 
All analyses were undertaken in Stata 14.0 (StataCorp.2015. Stata Statistical Software, College 
Station, TX, USA). 
 
Results 
Case characteristics 
Figure 1 illustrates the application of study inclusion criteria and the HPV diagnostic testing 
algorithm. Valid results were obtained for 1474 cases obtained from 11 centres. Sample 
characteristics (gender, age at diagnosis, oropharyngeal subsite, year of diagnosis and study centre) 
are shown in Table 1. The mean age of patients was 59.3 years, 75.0% of patients were male, and 
the majority of cases (57.9%) were tonsil cancers. Invalid results were obtained for 55 patients and 
these were excluded from the analysis. The age, gender and subsite distribution were similar for the 
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included and excluded samples, and excluded samples were evenly distributed across the study 
period. The reasons for exclusion were either absence of tumour in the TMA cores or loss of TMA 
cores during processing for staining. 
The age and gender distributions were compared between OPSCC cases included in the current 
study, and those reported by UK Cancer Registries for the same period (Supplementary Table S1). 
The study sample included 8.3% of the 17739 OPSCC diagnosed in the UK 2002-2011. The gender 
balance between the current study (75% Male) and the UK OPSCC population (73.5% Male) was 
similar. There was a higher proportion of younger patients (45-54.9 years) in the study sample 
(30.4%) than in the OPSCC population overall (25.7%) (p=0.001); however the age distribution for 
cases in the two halves of the study period was similar (2002-2006 vs.2007-2011,p=0.5) 
(Supplementary Table S2).    
 
HPV Prevalence 
The prevalence of HPV infection in OPSCC was 51.8% (95% CI:49.3, 54.4). The prevalence of HPV 
infection within specific subgroups is shown in Table 2.  The proportion of HPV-positive cases was 
higher in men than women (54.3% vs.44.4%), and decreased with increasing age (69.2% in patients 
aged less than 44 years vs.37.2% in patients aged over 75 years). The mean age of patients with HPV-
positive disease was 57.4 years compared to 61.4 years for HPV-negative cases (p<0.001). The 
prevalence of HPV infection varied depending on the tumour site, with the tonsil subsite showing 
the highest prevalence (61.8%), and soft palate/uvula showing the lowest (9.1%). HPV prevalence 
also varied between study centres, from 67.5% (95% CI:59.7, 74.4) in Liverpool to 35.4% (95% 
CI:27.0, 44.8) in Belfast.  The variation in the overall proportion of samples defined as positive by 
each test (53.7% p16-positive, 45.0% ISH-positive, 66.6% PCR-positive) is consistent with published 
literature, and reflects the established sensitivities and specificities of the assays.[12-14]  
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There appeared to be little variation in prevalence across the 10-year study period (Figure 2), either 
with HPV-positives defined using the stepwise algorithm, or for individual tests. Statistical models 
were used to assess change in the proportion of HPV-positive cases per year; the unadjusted risk 
ratio was 1.00 (95% CI:0.99, 1.02) for HPV infection for each year compared to the previous year (p 
for linear trend = 0.6), and the risk ratio adjusted for gender, age at diagnosis, anatomical subsite 
and study centre was 1.00 (95% CI:0.98,1.03) (p value for linear trend=0.7). This confirmed the 
absence of change in the proportion of HPV-positive samples over time. 
 
Type-specific HPV prevalence 
Among the 764 HPV-positive OPSCC, the Optiplex HPV Genotyping Kit identified a specific high-risk 
HPV type in 732 cases. In 710 (97%) of these cases, a single HPV type was present; the remaining 22 
samples contained DNA of more than one HPV type. Among cases in which a single HPV type 
detected, HPV16 was present in 684/710 cases (96.3%; 95% CI:94.7, 97.6) and HPV 18 in 11/710 
cases (1.5%; 95% CI:0.8, 2.8) (Supplementary table S3). Among cases classified as HPV-positive, HPV 
16 and/or 18 were identified in 714/764 (93.5%; 95% CI:91.5, 95.1). HPV33 was detected in 20 cases 
(2.6%; 95% CI:1.6, 4.0); in 9 of these cases, HPV16 was also present.  
 
Incidence of cancers of the oropharynx, larynx and mouth 2002-11, and estimated HPV-associated 
OPSCC disease burden  
Between 2002 and 2011 the UK incidence of OPSCC increased by 100.6%, while the incidence of 
laryngeal cancer increased by 9.3% (Figure 3). The majority of OPSCC occurred in men (2011 ASR: 6.3 
male vs 2.1 female). Laryngeal cancers were similarly more common in men than women (2011 ASR: 
7.1 vs 1.3). The incidence of mouth cancers increased by 45.4%, and there was a smaller difference 
in incidence between men and women than was observed with OPSCC and laryngeal cancers (2011 
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ASR: 3.7 vs 2.4).   
To estimate the burden of oropharyngeal cancers caused by HPV over this period, the proportions 
determined in the current study were applied to the incidence data (Figure 4). Figure 4 highlights 
increasing incidence of both HPV-positive and negative OPSCC, especially in men. It was notable that 
incidence curves for HPV-negative OPSCC and mouth cancers show very similar trends. With regard 
to non-HPV associated head and neck cancers in males, substantial absolute increases in ASR were 
observed for HPV-negative OPSCC, and for mouth cancers, with a smaller increase in laryngeal 
cancers (1.72, 1.14, and 0.73 /100,000 respectively).   
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Discussion 
This first nation-wide study investigating the prevalence of HPV in OPSCC within the UK showed that 
51.8% (95% CI:49.3, 54.4) of cases diagnosed between 2002 and 2011 were HPV-positive. Over the 
same period, the incidence of OPSCC in the broader population approximately doubled (ASR 
2002:2.1, ASR 2011:4.1), whilst the relative proportions of HPV-positive and negative OPSCC 
remained stable over time. These data demonstrate a parallel rise in HPV-positive and negative 
disease incidence that has not previously been reported and show that, in the UK at least, the 
increasing incidence of OPSCC, cannot be explained solely by an increase in HPV-associated disease.  
The strengths of the study include: large sample size; broad geographical representation; rigorous 
and systematic case selection; and, use of well-validated commercial tests to identify HPV tumour 
status. The results are likely to reflect national trends, although there is potential for variation in 
OPSCC incidence, and in HPV prevalence, between different geographical areas in the UK. To assess 
potential bias in case selection, the records supplied by each centre were formally reviewed. This 
showed that FFPE blocks from only nine patients were unavailable due to use in other clinical 
studies. The study group included a higher proportion of younger patients (45-54.9 yrs) relative to 
the OPSCC population, but given the younger mean age for HPV-positive patients, this would be 
more likely to result in overestimation of the proportion of HPV-associated disease, rather than 
underestimation. The HPV testing regime included three independent, well-validated, commercial 
tests (IHC, ISH and PCR), performed in independent laboratories and the three tests showed highly 
similar trends in HPV prevalence (Figure 2). The analysis of data pertaining to behavioural factors, 
such as smoking and sexual history, could potentially have allowed further interpretation of our 
results, however due to the retrospective nature of sample and data collection these data could not 
be reliably obtained.  
It is important to stress that conclusions based on the data presented should not be generalized 
beyond the UK. Substantial variation has been reported in the proportion of OPSCC attributable to 
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HPV between countries and time periods.[10, 11] This is likely to be a reflection of variations in 
multiple factors, including sexual behaviour and rates of genital HPV infection, as well as tobacco 
and alcohol consumption. This highlights that trends in the aetiology of OPSCC must be considered 
in a population-specific manner. Previous small, single centre studies from the UK reported HPV 
prevalence rates in OPSCC of 37.5% (95% CI:28, 48%), 42.7% (95% CI:36, 50%), and 55% (95% CI:45, 
66%).[12-14] The current study is consistent with these, but is based on a much larger sample with 
broader geographical representation, including centres in all four countries of the UK. We observed 
a consistent proportion of HPV-positive OPSCC over time from 2002 to 2011, against a background 
of increasing incidence. This contrasts with previous data, detailing an increased proportion of HPV-
positive OPSCC associated with increasing incidence of OPSCC overall.[8] Recent data from North 
America[10] and Stockholm,[23] however, suggest that plateaus in the proportion of HPV-positive 
OPSCC and HPV-positive tonsillar squamous cell carcinoma respectively, have been observed from 
the year 2000 onwards.  
The absence of change in the proportion of HPV-associated disease, despite a continued rise in 
incidence of OPSCC, implies that HPV-negative OPSCC, traditionally associated primarily with 
smoking[24], is also increasing in incidence. However, this contrasts with the more modest increase 
in incidence of other smoking-related head and neck malignancies, such as laryngeal cancer,[25] 
(Figure 3) and suggests that another risk factor, in addition to HPV and smoking, may contribute to 
the increased overall incidence of OPSCC. Prior tonsillectomy appears to reduce risk of tonsillar 
carcinoma,[26, 27] but while the current UK tonsillectomy rate is approximately 75% lower than in 
the 1950s,[28] the absence of a disproportionate increase in OPSCCs specifically involving the tonsils, 
in our results and other published data,[25] suggests this is not a major contributory factor to the 
increasing incidence of OPSCC. The observed increases in ASR among the different subsites (non-HPV 
OPSCC, mouth, and laryngeal) may reflect the degree of exposure of specific anatomical sites to 
individual carcinogens, including alcohol and tobacco smoke. In an analysis of Dutch HNSCC 
incidence, van Monsjou et al.[29] suggested that behavioural changes in the post-World War II 
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generation included reduced smoking rates coupled with significant rises in alcohol consumption 
and they suggested that excessive alcohol intake may be a more critical risk factor for OPSCC than 
smoking. In the UK, smoking rates have declined from 46% of adults in 1974 to 20% in 2010[30, 31]. 
However, since 1950, per capita alcohol consumption has increased from 3.9 L/year to a peak of 9.4 
L/year in 2004[32]. This appears consistent with the increasing incidence of cancers at sites with 
greater exposure to alcohol (e.g mouth) but smaller increases at sites more strongly associated with 
tobacco smoking (e.g. larynx).  
It is probable that gender-neutral prophylactic HPV vaccination could prevent HPV-positive 
OPSCC.[33] Indeed national bodies, such as the Joint Committee on Vaccination and Immunisation in 
the UK, are currently considering extending prophylactic HPV vaccination to include boys, as well as 
girls. Our data substantially expand the evidence base available to inform decisions such as this, 
particularly when viewed in the context of a projected substantial continued rise in OPSCC incidence 
of up to 239% in the next 20 years.[34] The current bivalent and quadrivalent HPV vaccines protect 
against infection with oncogenic HPV types 16 and 18; these types were present in 714/764 cases 
(93.5%; 95%CI 91.5,95.1) of HPV-positive OPSCC in our study. Our data suggest that of the 1781 
cases of OPSCC diagnosed in men in the UK in 2011, approximately 926 were HPV-positive, and 866 
were associated with HPV types included in current vaccines.  
The parallel increase in both HPV-positive and HPV-negative tumours should be of concern to those 
involved in the clinical management of OPSCC, and to public health officials charged with developing 
strategies to reduce incidence. The data presented highlight that in the UK, increases in OPSCC 
incidence are not entirely due to HPV-associated disease. However, these findings should not be 
extrapolated to other developed world populations, rather, they emphasise the need to assess the 
aetiology of head and neck cancers, and oropharyngeal cancers in particular, on a population specific 
basis.   
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Tables 
Table 1. Characteristics of included/excluded cases 
Variable Included in study (n=1474) 
Excluded from study 
(n=55) 
P value for 
differencea 
  Mean Standard deviation Mean 
Standard 
deviation   
Age at diagnosis 59.3 years 10.7 years 57.3 years 8.6 years 0.2 
  Frequency Percentage Frequency Percentage   
Gender 
M  1150 75.0  32 58.2 
0.01 
F 369 25.0  23 41.8 
Oropharyngeal 
Subsite 
Tonsil 854  57.9 26 47.3 
0.1 
Base of Tongue 362  24.6 20 36.4 
Soft palate 88  6.0 5 9.1 
Oropharynx NOSb 170  11.5 4 7.3 
Year of 
diagnosis 
2002 118  8.0 6 10.9 
0.7 
2003 133  9.0 4 7.3 
2004 135  9.2 9 16.4 
2005 148  10.0 5 9.1 
2006 156  10.6 5 9.1 
2007 159  10.8 7 12.7 
2008 168  11.4 3 5.5 
2009 149  10.1 4 7.3 
2010 145  9.8 6 10.9 
2011 163  11.1 6 10.9 
Study Centre 
Belfastc 113 7.7 2 3.6 
<0.001 
Bristol 65 4.4 0 0 
Cardiffd 149 10.1 4 7.3 
Coventry 92 6.2 7 12.7 
Edinburghe 108 7.3 27 49.1 
Liverpool 157 10.7 4 7.3 
Londonf 158 10.7 4 7.3 
Manchesterg 166 11.3 0 0 
Newcastle 170 11.5 0 0 
Poole 116 7.9 7 12.7 
Southampton 180 12.2 0 0 
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Table 2. Associations between characteristics and HPV status  
 
  HPV Prevalence (%)a 95% CI 
         All samples                                                51.8 49.3, 54.4 
Gender 
Male 54.3 51.3, 57.2 
Female 44.4 39.4, 49.6 
Age at diagnosis  
≤ 44.9 years 69.2 59.6, 77.5 
45-54.9 years 61.4 56.8, 65.8 
55-64.9 years 48.9 44.6, 53.3 
65-74.9 years 42.3 36.7, 48.1 
≥ 75 years 37.2 29.2, 46.0 
Oropharyngeal 
Subsite 
Tonsil 61.8 58.5, 65.0 
Base of Tongue 49.4 44.3, 54.7 
Soft palate/Uvula 9.1 4.5, 17.3 
Oropharynx NOSb 28.8 22.5, 36.2 
Year of diagnosis 
2002 50.0 40.9, 59.1 
2003 48.1 39.7, 56.7 
2004 52.6 44.1, 61.0 
2005 54.1 45.9, 62.0 
2006 47.4 39.6, 55.4 
2007 55.4 37.0, 52.5 
2008 54.2 46.5, 61.6 
2009 53.7 45.6, 61.6 
2010 53.1 44.9, 61.2 
2011 49.1 41.4, 56.8 
Study Centre 
Belfast 35.4 27.0, 44.8 
Bristol 43.1 31.4, 55.6 
Cardiff 62.4 54.3, 69.9 
Coventry 41.3 31.6, 51.8 
Edinburgh 45.4 36.1, 55.0 
Liverpool 67.5 59.7, 74.4 
London 65.2 57.4, 72.3 
Manchester 51.2 43.6, 58.8 
Newcastle 44.1 36.8, 51.7 
Poole 52.6 43.4, 61.6 
Southampton 47.8 40.5, 55.1 
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Legends for Tables & Figures: 
 
Table 1: Characteristics of included/excluded cases 
ap value for comparison between those included/excluded from the study, t-test for mean(SD), chi-
squared test for percentages. 
bNOS – Not Otherwise Specified. 
cBelfast – samples were accessed via The Northern Ireland Biobank from the Belfast Health and 
Social Care Trust archives which serves the Royal Victoria Hospital and the Belfast City Hospital. 
dCardiff – samples were collected via Velindre Cancer Centre, which serves all of South East Wales. 
eEdinburgh – samples were collected via the East of Scotland Cancer Centre which serves Edinburgh 
and surrounding areas, Dumfries and Galloway, Fife and the Scottish Borders.     
fLondon – samples were collected via Royal Marsden Hospital, which serves South West and West 
London, with additional referrals from Sussex and Kent.  
gManchester – samples were collected via the Christie NHS Foundation Trust, which serves Greater 
Manchester and parts of Cheshire. 
 
Table 2. Associations between characteristics and HPV status  
aHPV prevalence defined according to tier-wise algorithm. 
bNOS – Not Otherwise Specified. 
 
Figure 1. Study schema 
The HPV testing algorithm was applied in three tiers. 1474 of 1529 samples were successfully 
classified as HPV positive (red boxes) or negative (blue boxes). 55 samples gave invalid data (grey 
boxes).  
 
Figure 2. Proportion of OPSCC testing HPV positive over time, by individual test and algorithm 
The red line represents the proportion of samples classified as HPV positive using the algorithm 
shown in Figure 1. Other lines show the results of individual tests.  
 
Figure 3.  Incidence of SSC of the oropharynx, larynx and mouth (UK, 2002-2011) 
OPSCC indicates Oropharyngeal Squamous Cell Carcinoma; LSCC indicates Laryngeal Squamous Cell 
Carcinoma; Mouth comprises malignant neoplasms of the gum, floor of mouth, palate (excluding 
soft palate and uvula), and other and unspecified parts of the mouth.  
 
Figure 4.  Estimated incidence of OPSCC by HPV status (UK, 2002-2011) 
For each year, the gender-specific proportion of HPV positive samples was multiplied by the gender-
specific incidence to estimate ASR for both HPV positive and negative OPSCC. Incidence of cancers of 
the mouth is also shown. 
 
 
 
 
 
Figure 1. Study schema 
The HPV testing algorithm was applied in three tiers. 1474 of 1529 samples were successfully 
classified as HPV positive (red boxes) or negative (blue boxes). 55 samples gave invalid data (grey 
boxes).  
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Figure 2. Proportion of OPSCC testing HPV positive over time, by individual test and 
algorithm 
The red line represents the proportion of samples classified as HPV positive using the algorithm 
shown in Figure 1. Other lines show the results of individual tests.  
Figure 3.  Incidence of SSC of the oropharynx, larynx and mouth (UK, 2002-2011) 
OPSCC indicates Oropharyngeal Squamous Cell Carcinoma; LSCC indicates Laryngeal Squamous 
Cell Carcinoma; Mouth comprises malignant neoplasms of the gum, floor of mouth, palate 
(excluding soft palate and uvula), and other and unspecified parts of the mouth.  
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Figure 4.  Estimated incidence of OPSCC by HPV status (UK, 2002-2011) 
For each year, the gender-specific proportion of HPV positive samples was multiplied by the 
gender-specific incidence to estimate ASR for both HPV positive and negative OPSCC. Incidence 
of cancers of the mouth is also shown. 
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